此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of SHR 3201 Injection in Healthy Participants

2026年11月17日 更新者:Beijing Suncadia Pharmaceuticals Co., Ltd

A Randomized, Double Blind, Dose Escalation, Placebo Controlled Phase I Clinical Trial to Evaluate the Safety, Tolerability and Pharmacokinetics of Single Intravenous and Subcutaneous Administrations of SHR 3201 Injection in Healthy Participants

This study is a randomized, double-blind, dose-escalation, placebo-controlled Phase I clinical trial in healthy participants to evaluate the safety, tolerability, and pharmacokinetics of single intravenous and subcutaneous administrations of SHR-3201.

研究概览

研究类型

介入性

注册 (估计的)

50

阶段

  • 阶段1

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习联系方式

研究联系人备份

学习地点

    • Anhui
      • Hefei、Anhui、中国、230000
        • 招聘中
        • The First Affiliated Hospital of University of Science and Technology of China
        • 首席研究员:
          • Jiong Shi
        • 首席研究员:
          • Zhaoyi Yang
        • 接触:
        • 接触:

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 60年 (成人)

接受健康志愿者

是的

有资格学习的性别

全部

描述

Inclusion Criteria:

  1. Healthy male or female participants aged 18 to 60 years (inclusive) at the time of informed consent signing;
  2. Male participants weighing ≥ 50.0 kg, and female participants weighing ≥ 45.0 kg, with a body mass index (BMI) between 19.0 and 28.0 kg/m² (inclusive), where BMI = weight (kg) / height² (m²);
  3. Female participants of child bearing potential shall agree to contraception and oocyte donation avoidance from ICF signature to 6 months after last investigational product dose, with negative serum pregnancy tests at screening and baseline. Male participants shall agree to highly effective contraception and sperm donation avoidance from ICF signature to 6 months after last investigational product dose;
  4. Ability to understand the study procedures and requirements, willingness to participate voluntarily, and provide written informed consent.

Exclusion Criteria:

  1. Participants with past or current acute or chronic disorders of the circulatory, endocrine, nervous, digestive, respiratory, hematological, immunological, psychiatric systems or metabolic abnormalities, as assessed by the Investigator to be unsuitable for study enrollment;
  2. Have a history of drug or other allergies, or, in the investigator's judgment, may be allergic to the investigational product or any of its components;
  3. Have undergone major surgery within 6 months prior to screening, or have undergone surgery that may significantly affect the in vivo disposition of the investigational product or the safety evaluation, or plan to undergo surgery during the trial period;
  4. Have participated in any clinical trial as a participant within 3 months prior to Screening, or plan to participate in other clinical trials during the course of this study;
  5. Have experienced blood loss or donated blood > 400 mL (excluding menstrual blood loss in females), received blood transfusion or blood products within 3 months prior to Screening, or plan to donate blood during the trial or within 1 month after the end of the trial;
  6. Cannot tolerate MRI or have MRI contraindications, including but not limited to cardiac pacemaker, defibrillator, artificial heart valve or other metallic implants; or other conditions assessed by the Investigator that may cause potential risks during MRI scanning;
  7. Have any laboratory abnormalities at screening, or have clinically significant abnormalities in vital signs, physical examinations, or laboratory tests specified in the protocol as judged by the investigator;
  8. Have chest X-ray (posteroanterior view) or abdominal ultrasound findings at Screening judged by the investigator to be clinically significant abnormalities;
  9. Have positive results at Screening for any of the following: hepatitis B surface antigen (HBsAg), hepatitis C virus antibody (HCV-Ab), or Treponema pallidum antibody (Anti-TP);
  10. Have used or are currently using any prescription drugs or over-the-counter (OTC) medications within 2 weeks prior to dosing; or have taken functional vitamins, health supplements, or herbal products; or are known to require other medication during the trial period;
  11. Have consumed excessive amounts of tea, coffee, or caffeinated beverages (average > 8 cups per day, 200 mL per cup) within 3 months prior to screening;
  12. Have consumed special foods (e.g., grapefruit, grapefruit juice, or food/beverages containing grapefruit juice, chocolate, tobacco, alcohol, caffeinated products, etc.) within 48 hours prior to dosing;
  13. Have a history of regular alcohol consumption (i.e., > 14 standard units per week within 3 months prior to Screening, where 1 standard unit contains 14 g of alcohol, equivalent to 285 mL of beer, 25 mL of 40% spirit, or 85 mL of wine), or are unable to abstain from alcohol during the trial; or have a positive alcohol breath test;
  14. Have an average daily smoking history of > 5 cigarettes per day within 3 months prior to Screening, or are unable to abstain from smoking during the trial;
  15. Have a history of drug abuse or substance use; or have a positive result on drug abuse screening (including MDMA, methamphetamine, morphine, ketamine, and THC acid);
  16. Are pregnant or lactating females;
  17. Have difficulty with venous blood sampling, are unable to tolerate venipuncture, or have a history of needle or blood phobia;
  18. Participants who, in the opinion of the investigator, may be unable to complete the study for other reasons, or who are considered unsuitable for enrollment by the investigator.

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:治疗
  • 分配:随机化
  • 介入模型:并行分配
  • 屏蔽:四人间

武器和干预

参与者组/臂
干预/治疗
实验性的:Dose 1 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 1.

SHR 3201 injection.

SHR 3201 placebo.

实验性的:Dose 2 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 2.

SHR 3201 injection.

SHR 3201 placebo.

实验性的:Dose 3 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 3.

SHR 3201 injection.

SHR 3201 placebo.

实验性的:Dose 4 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 4.

SHR 3201 injection.

SHR 3201 placebo.

实验性的:Dose 5 Group: SHR-3201 + Placebo

SHR-3201, SHR-3201 Placebo, in Dose 5.

SHR 3201 injection.

SHR 3201 placebo.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Adverse events (AEs)
大体时间:From pre-dose to 36 days post-dose.
From pre-dose to 36 days post-dose.

次要结果测量

结果测量
大体时间
Serum concentration of SHR-3201 after single-dose administration
大体时间:From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Area Under the Concentration (AUC) of SHR-3201 after single administration (AUC0-last, AUC0-inf)
大体时间:From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Time to peak concentration (Tmax)
大体时间:From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Peak concentration (Cmax)
大体时间:From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Elimination half-life (T1/2)
大体时间:From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Clearance (CL)
大体时间:From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Steady-state volume of distribution (Vss)
大体时间:From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Bioavailability of SHR-3201 following subcutaneous administration
大体时间:From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.
Incidence of anti-drug antibodies (ADA)
大体时间:From pre-dose to 29 days post-dose.
From pre-dose to 29 days post-dose.

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2026年11月9日

初级完成 (估计的)

2027年1月1日

研究完成 (估计的)

2027年2月1日

研究注册日期

首次提交

2026年10月16日

首先提交符合 QC 标准的

2026年10月16日

首次发布 (实际的)

2026年10月22日

研究记录更新

最后更新发布 (实际的)

2026年11月20日

上次提交的符合 QC 标准的更新

2026年11月17日

最后验证

2026年11月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

未定

药物和器械信息、研究文件

研究美国 FDA 监管的药品

不

研究美国 FDA 监管的设备产品

不

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅